What is the current stock price of Apollomics, Inc. (APLM)?

As of the latest market data, Apollomics, Inc. (APLM) is trading at $13.60. The stock has seen a loss of -8.42% today.

Does Apollomics, Inc. (APLM) pay a dividend?

Based on current data, Apollomics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Apollomics, Inc.?

The current market capitalization of Apollomics, Inc. (APLM) is approximately unavailable.

APLM

Apollomics, Inc.·Healthcare

13.60

8.418%(−1.25)

Market Closed

15.69

15.368%(+2.09)

After Hours

Last Updated: — ET

52W L: $3.6652W H: $42.12

APLM NEWS

globenewswire.com

Apr 1

Apollomics Inc. Announces $2.0 Million Bridge Financing

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr.

defenseworld.net

Mar 28

Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March

Apollomics Inc. (NASDAQ: APLM - Get Free Report) was the target of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,621 shares, a decline of 30.9% from the February 26th total of 12,471 shares. Approximately 0.8% of the shares of the company are sold

defenseworld.net

Mar 18

Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest

Apollomics Inc. (NASDAQ: APLM - Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 12,471 shares, a decline of 15.2% from the February 12th total of 14,705 shares. Approximately 1.1% of the company's shares are sold short. Based

Company Profile

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-11-26

Beta

1.83

Websitewww.apollomicsinc.com↗